Informed Choice and the Widespread Use of Antiinflammatory Drugs
|
|
- Harriet Gibbs
- 5 years ago
- Views:
Transcription
1 Arthritis & Rheumatism (Arthritis Care & Research) Vol. 51, No. 2, April 15, 2004, pp DOI /art , American College of Rheumatology ORIGINAL ARTICLE Informed Choice and the Widespread Use of Antiinflammatory Drugs LIANA FRAENKEL, 1 DICK R. WITTINK, 2 JOHN CONCATO, 1 AND TERRI FRIED 1 Objective. To examine whether the current widespread use of antiinflammatory drugs may reflect a lack of informed choice (i.e., unawareness of adverse effects or potential treatment alternatives) among older patients with knee osteoarthritis (OA). Methods. Consecutive patients with symptomatic knee OA (n 100) completed a questionnaire to assess their awareness of drug toxicity. Patients also completed an Adaptive Conjoint Analysis task so that the influence of providing an additional treatment alternative on patient preferences for nonselective nonsteroidal antiinflammatory drugs () and cyclooxygenase-2 (COX-2) inhibitors could be assessed. Results. Fifty-four percent of the patients surveyed were unaware of any adverse effects related to and 80% were unaware of any toxicity related to. When given a choice between and, 57% of patients preferred over. When presented with a third less effective, but safer alternative, 100% of patients switched preferences to the safer, albeit less effective, option. Conclusions. Our findings suggest that the widespread use of may reflect lack of informed choice among older patients with OA. KEY WORDS. Osteoarthritis; Nonsteroidal antiinflammatory drugs; Cyclooxygenase 2 inhibitors. INTRODUCTION Nonsteroidal antiinflammatory drugs () are the most widely used medications for patients with arthritis and other painful conditions, with 70 million to 100 million prescriptions written in the US per year. Cyclooxygenase-2 (COX-2) inhibitors continue to expand the market of antiinflammatory drugs, with total revenues expected to Presented in part at the 66th Annual Scientific Meeting of the American College of Rheumatology, New Orleans, LA, October Dr. Fraenkel s work supported by a VA Career Development Award. Dr. Fried s work supported by grant K02- AG20113 from the NIA. This study was supported by a grant through the Study of Health Care Relationships, a partnership between Yale University and the University of Connecticut, sponsored by the Donaghue Medical Research Foundation, and the Yale Pepper Center. This study was not supported by pharmaceutical industry funds. 1 Liana Fraenkel, MD, MPH, John Concato, MD, MS, MPH, Terri Fried, MD: Veteran s Affairs Connecticut Healthcare System and Yale University, New Haven, Connecticut; 2 Dick R. Wittink, PhD: Yale University, New Haven, Connecticut. Address correspondence to Liana Fraenkel, MD, MPH, Yale University, Department Internal Medicine, Section of Rheumatology, PO Box , 333 Cedar Street, New Haven, CT liana.fraenkel@yale.edu. Submitted for publication February 23, 2003; accepted in revised form July 2, exceed $2.5 billion by 2008 (1). The widespread use of contrasts with clinical studies that have demonstrated that, when fully informed of expected risk and benefits, older arthritis patients are reluctant to accept the risks of drug-related adverse effects (AEs) for modest drug benefits (2 4). One possible explanation for the discrepancy between patient risk aversion and the widespread use of antiinflammatory drugs is that patients may be unaware of the AEs related to this class of medications. This possibility is supported by previous studies demonstrating that many patients have limited knowledge about their medications (5 7) and that physicians disclose limited risk-related information when prescribing (8) as well as other medications (5). Another possible explanation is that patients do not explicitly consider the tradeoffs related to available treatment options. This possibility is supported by recent studies that have demonstrated that, despite efforts to promote shared decision making, patients tend to comply with physicians recommendations rather than participate in interactive discussions about available options (9 11). The objective of this study was to examine whether the widespread use of may reflect a lack of informed choice (i.e., unawareness of AEs or potential treatment alternatives) among patients with arthritis. To test this hypothesis, we 1) ascertained patient knowledge of arthri- 210
2 Informed Choice and NSAID Use 211 tis medications and their associated toxicity, and 2) assessed whether asking patients to consider additional options influences their preferences for and COX-2 inhibitors. METHODS Patients. Consecutive patients with radiographic knee osteoarthritis (OA), treated in community rheumatology practices affiliated with a university hospital, were contacted by telephone 1 week after having received a letter describing the study. Patients having pain in 1 or both knees on most days of the month and not having rheumatoid arthritis, gout, pseudogout, or bilateral knee replacements were asked to complete a questionnaire examining opinions about arthritis treatments. The study was approved by the Human Investigations Committee at our institution. Figure 1. Two examples of Adaptive Conjoint Analysis questions. Data collection. All data were collected in face-to-face interviews by a research assistant. Patient characteristics were based on self report and the Western Ontario and McMaster Universities Osteoarthritis Index (12). Patient knowledge regarding available treatment options for OA was ascertained using open-ended questions based on the Basic Arthritis Test (13): What medications are available to patients with your type of arthritis? Patients were classified as being aware of as a possible treatment option if they listed one or more generic or brand name. Patients were classified as being aware of COX-2 inhibitors if they listed the generic or brand name of either of the 2 coxibs available at the time of the study (rofecoxib and celecoxib). For each of the medications listed, patient awareness of AEs was ascertained using the following question (13): Name the possible side effects of this medication. Patients answering none or no side effects were classified as being unaware of AEs related to the medication(s) listed. We assessed treatment preferences using Adaptive Conjoint Analysis (ACA; version 4.0, Sawtooth Software, Sequim, WA), a well-validated interactive computer program that computes individual patient values (utilities) for specific medication characteristics based on a series of ranking and rating questions. ACA derives individual patient preferences based on the utilities derived from the conjoint questionnaire using least squares regression analyses (14). Because preferences are derived based on tradeoffs between treatment characteristics and not full descriptions of the medications, they are not influenced by product recognition or brand preferences. We ascertained patient values (i.e., utilities) for the following medication characteristics: time to benefit, response rate, common AEs, risk, and monthly copayments (reflective of 2001 pharmaceutical costs in Connecticut). All characteristics were described using lay terminology adapted from patient information sheets published by the Arthritis Foundation. The face and content validity of the characteristic descriptions were assessed by rheumatologists, conjoint experts, and lay persons. In view of the literature documenting significant variability in both patients ability to interpret probabilities and preference for the presentation of probabilistic information (15), we used qualitative and quantitative frequency formats to describe the likelihood of AEs. The ranges of probabilities of benefits and AEs were based on randomized controlled data and observational studies (16 24). The characteristics assigned to the treatment options studied are described in Table 1. ACA questionnaire. Respondents were first asked to rate the importance of the difference between the best and worst estimate of each characteristic on a 4-point scale. The characteristics were presented in random order to eliminate any possible ordering effects (Figure 1). Second, to refine respondents utilities, respondents evaluated a series of paired comparisons (Figure 1). A 9-point scale was used for paired comparisons so that finer differences in strength of preference could be derived. The program uses the information obtained from each paired comparison to update the estimates of each respondent s utilities and to select the next pair of options. Final utilities are then generated using regression analysis (14). Additional details regarding this methodology have been published previously (14,25 27). Analyses. Preference data derived from ACA were imported into SAS computer files (SAS software, version 6.12; SAS Institute, Cary, NC) and merged with the patient characteristics data set. We used ACA to determine the percentage of patients preferring specific treatment options. ACA is capable of performing choice simulations that demonstrate the percentage of patients preferring specific treatment options defined by the researcher (14). Individual patient preferences are derived based on each patient s responses to the rating and paired-comparison tasks (27). We first examined treatment preferences for medications
3 212 Fraenkel et al Table 1. Description of treatment options studied* Characteristic Alternative 1 Alternative 2 Alternative 3 Alternative 4 Route of po bid po qd po qd po qid po qid po qid administration Onset of action 1 2 hours 1 2 hours 1 2 hours Within 4 Within 4 Within 4 Percent of patients 50% 50% 25% 25% 25% 25% who benefit Common adverse Nausea, diarrhea, Nausea, diarrhea, Well tolerated Well tolerated Well tolerated Well tolerated effects heartburn heartburn Annual risk 2% 1% Out-of-pocket cost per month $17.50 $70.00 $17.50 $17.50 $25 $50 * nonsteroidal antiinflammatory drugs; COX-2 cyclooxygenase 2; po by mouth; bid twice a day; qd every day; qid 4 times a day. describing and using ACA s simulation capabilities. We subsequently examined the influence of adding a third, safer but less effective, treatment option on patient preferences. RESULTS Older adults with symptomatic knee OA were interviewed (n 100, participation rate 84%). The mean SD age of our sample was 70 7 years (range years); 79% were female, 92% were white, 69% had some college education, and 32% reported having an annual household income $60,000. The mean SD duration of knee pain was 11 9 years; mean SD knee pain score was 12 4 (on a scale of 0 20), and mean SD physical function score was (on a scale of 0 68). Thirty-five percent reported previously having dyspepsia due to, 22% had an ulcer, and 5% had been hospitalized for a gastrointestinal bleed. The majority of patients reported current or previous use of (85%) and (76%) (Table 2). Eighty percent of patients listed and 81% listed as possible therapeutic options (Table 3). Of these, 54% were unaware of any AEs related to and 80% were unaware of any toxicity related to COX-2 inhibitors. Patients reporting previous gastrointestinal AEs due to antiinflammatory medications and those with longer duration of knee OA symptoms were more likely to be aware of at least 1 AE associated with compared with those without prior AEs and shorter duration of Table 2. Utilization of and among the 100 patients surveyed* Current use, no Past use, no Never used, no Don t know, no. 3 6 * nonsteroidal antiinflammatory drugs; COX-2 cyclooxygenase 2. symptoms (Table 4). In a logistic regression model containing all 5 variables, previous gastrointestinal AEs remained a clinically significant predictor of awareness of AEs related to. The adjusted odds ratio [OR] for gastrointestinal AEs was 4.5, 95% confidence interval [95% CI] ; and for duration of knee OA 1.1, 95% CI The number of patients aware of AEs related to COX-2 inhibitors was very small, making it difficult to examine associations between patient characteristics and awareness of drug toxicity (Table 4). Fifty-seven percent of patients preferred over (Table 5). Adding a third option that is 50% less effective but does not cause dyspepsia or serious gastrointestinal events resulted in a dramatic change in preferences, with 100% of patients preferring the safer, but less effective option (Table 5). If the third alternative is described as having a delayed onset of action (4 ) and must be taken 4 times daily, the number preferring this option drops to 69%. Fifty percent of the patients surveyed continued to prefer the less effective, less convenient, but safer option, even when it costs more than double the cost of the option describing traditional. We found no relationship between the percentage of patients preferring the additional option and age, income, education, pain, functional status, or previous gastrointestinal side effects (data not shown). DISCUSSION Many older patients with knee OA in this well-educated cohort were unaware of the toxicity associated with Table 3. Percentage of patients unaware of the specific adverse effects associated with antiinflammatory drugs* Adverse effect (n 80) % (n 81) % Stomach upset/heartburn Ulcer/GI bleed Renal toxicity * nonsteroidal antiinflammatory drugs; COX-2 cyclooxygenase 2; GI gastrointestinal.
4 Informed Choice and NSAID Use 213 Table 4. Association between patient characteristics and knowledge of adverse effects* Characteristics Aware of AEs (n 37) Unaware of AEs (n 43) P Aware of AEs (n 16) Unaware of AEs (n 65) P Age, mean SD years College education, % Annual household income $60,000, % Previous gastrointestinal AEs, % Duration of OA, mean SD years * nonsteroidal antiinflammatory drugs; COX-2 cyclooxygenase:2; AEs adverse effects; OA osteoarthritis., and almost all were unaware of the toxicity associated with. Awareness of NSAID-related toxicity was associated with duration of knee OA and previous experience of gastrointestinal AEs. These results are in agreement with a survey in which 55% of Americans taking were unaware of NSAID-related gastrointestinal complications (7), and are supported by the study by Katz et al (8) that demonstrated that rheumatologists disclose relatively minimal information when prescribing. To the best of our knowledge, patient awareness regarding the toxicity associated with COX-2 inhibitors has not been previously studied. Taken together, these findings suggest that, while most arthritis patients are currently or have previously used or, they may not be fully informed of the potential risks associated with these medications. We also found that, when given a choice, older adults almost always opt for safer (albeit less effective) medications over treatment options with known (even if small) risks of toxicity. We would expect that even fewer patients would choose antiinflammatory drugs had we included other drug-related risks, such as renal toxicity. These results suggest that many older patients might want to try relatively safer treatment options, such as capsaicin, before agreeing to accept the gastrointestinal toxicity associated with antiinflammatory drugs. Our results must be interpreted in view of the limitations of the study. ACA derives individual patient preferences based on how each patient values tradeoffs between specific medication characteristics. Therefore, while providing preference data that is unbiased by brand name recognition and providers preferences, this method is limited by the spectrum of characteristics included in the ACA survey. In addition, we measured preferences at only one point in time; one would expect that patient preferences would change depending on response to treatment and development of AEs. The relatively uniform and small population studied limits the generalizability of our results. Although NSAID use and AEs experienced in this cohort are within the ranges of those reported in the general arthritis population (7), it is possible that younger patients or those with more severe disease would be more willing to accept the risks associated with and. Last, the number of patients preferring antiinflammatory drugs might have decreased simply as a result of adding a third alternative. However, the dramatic switch in preferences observed would be unlikely to occur solely on the basis of expanding the choice set. Our findings have important ethical and clinical implications. First, this study adds to the literature suggesting that older patients may not be adequately informed of the risks associated with antiinflammatory medications. This finding is worrisome because older patients are among those at the highest risk for serious gastrointestinal complications, and are the most frequent chronic users of Table 5. Treatment preferences for,, and a third treatment option* Description of the additional treatment option Preferring Preferring Preferring third option Alternative 1: No AEs, 50% less effective, $17.50/month. Alternative 2: No AEs, 50% less effective, $17.50 per month. Alternative 3: No AEs, 50% less effective, $25.00 per month. Alternative 4: No AEs, 50% less effective, $50.00 per month * nonsteroidal antiinflammatory drugs; COX-2 cyclooxygenase 2; AEs adverse effects; qid 4 times a day.
5 214 Fraenkel et al antiinflammatory medications. Second, we found that the widespread use of these drugs (as described in this study) is not consistent with patient preferences, and that when given a choice, many patients opt for safer, albeit less effective, alternatives. This finding is particularly important because do not affect the natural history of the disease. In summary, this study suggests that the widespread use of antiinflammatory drugs may, in part, reflect lack of informed choice among older patients with OA. Health care providers should encourage patient participation in decision-making to ensure informed choice among older adults with arthritis. ACKNOWLEDGMENTS We thank Drs. R. T. Schoen, J. Kenney, C. DiSabatino, A. Liebling, J. Evans, D. Trock, M. Schwartz, R. Maclean, and C. Arnold for their help in recruiting patients. Most importantly, we thank all the patients who participated in this study for their time and effort. REFERENCES 1. IMS Health Web site. Accessed January 16, URL: www. imshealth.com. 2. Fraenkel L, Bogardus S, Concato J, Felson D. Does decreasing the likelihood of toxicity make patients more likely to use medications? J Rheumatol 2003;30: O Brien BJ, Elswood J, Calin A. Willingness to accept risk in the treatment of rheumatic disease. J Epidemiol Community Health 1990;44: Pullar T, Wright V, Feely M. What do patients and rheumatologists regard as an acceptable risk in the treatment of rheumatic disease? Br J Rheumatol 1990;29: Ascione FJ, Kirscht JP, Shimp LA. An assessment of different components of patient medication knowledge. Med Care 1986;24: Ribeiro V, Blakeley J, Laryea M. Women s knowledge and practices regarding the prevention and treatment of osteoporosis. Health Care Women Int 2000;21: Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;Suppl 26: Katz JN, Daltroy LH, Brennan TA, Liang MH. Informed consent and the prescription of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1992;35: O Cathain A, Walters SJ, Nicholl JP, Thomas KJ, MKirkham M. Use of evidence based leaflets to promote informed choice in maternity care: randomised controlled trial in everyday practice. BMJ 2002;324: Oliver S, Rajan L, Turner H, Oakley A, Entwistle V, Watt I, et al. Informed choice for users of health services: views on ultrasonography leaflets of women in early pregnancy, midwives, and ultrasonographers. BMJ 1996;313: Stapleton H, Kirkham M, Thomas G. Qualitative study of evidence based leaflets in maternity care. BMJ 2002;324: Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15: Branch VK, Lipsky K, Nieman T, Lipsky PE. Positive impact of an intervention by arthritis patient educators on knowledge and satisfaction of patients in a rheumatology practice. Arthritis Care Res 1999;12: Johnson RM. Adaptive conjoint analysis: Sawtooth Software conference proceedings. Sequim (WA): Sawtooth Software; p Mazur DJ, Hickam DH. Patients interpretations of probability terms. J Gen Intern Med 1991;6: Altman RD, Moskowitz R. A randomized clinical trial of intra-articular sodium hyaluronate in patients with osteoarthritis of the knee: a summary. Am J Orthop 1999;28(11 Suppl): Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000;43: Deal CL, Schnitzer TJ, Lipstein E, Seibold JR, Stevens RM, Levy MD, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991;13: Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, et al, Rofecoxib Osteoarthritis Pilot Study Group. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999;26: Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999;26: Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with. JAMA 1999;282: Peloso PM, Bellamy N, Bensen W, Thomson GT, Harsanyi Z, Babul N, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000;27: Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000; 160: Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with emphasis on trial methodology. Semin Arthritis Rheum 1997;26: Fraenkel L, Bogardus ST, Wittink DR. Understanding patient preferences for the treatment of lupus nephritis using adaptive conjoint analysis. Med Care 2001;39: Green PE, Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. J Marketing 1990;54: Wittink DR, Bergenstuen T. Forecasting with conjoint analysis. In: Armstrong JS, editor. Principles of forecasting: a handbook for researchers and practitioners. Norwell (MA): Kluwer Academic Publishers; 2001.
Osteoarthritis (OA), the most common joint
Effect of Rofecoxib Therapy on Measures of Health-Related Quality of Life in Patients With Osteoarthritis Elliot W. Ehrich, MD; James A. Bolognese, MStat; Douglas J. Watson, PhD; and Sheldon X. Kong, PhD
More informationI n 1992, Felson et al compared available treatment options
1372 EXTENDED REPORT Patient preferences for treatment of rheumatoid arthritis L Fraenkel, S T Bogardus, J Concato, D T Felson, D R Wittink... See end of article for authors affiliations... Correspondence
More informationEfficacy and tolerability of celecoxib in osteoarthritis patients who previously failed naproxen and ibuprofen: results from two trials
International Journal of Clinical Rheumatology A - Efficacy and tolerability of celecoxib in osteoarthritis patients who previously failed naproxen and ibuprofen: results from two trials Aims: To evaluate
More informationGastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict?
Vol. 23 No. 4S April 2002 Journal of Pain and Symptom Management S5 Proceedings from the Symposium The Evolution of Anti-Inflammatory Treatments in Arthritis: Current and Future Perspectives Gastrointestinal
More informationT Pincus, G Koch, H Lei, B Mangal, T Sokka, R Moskowitz, F Wolfe, A Gibofsky, L Simon, S Zlotnick, J G Fort...
931 EXTENDED REPORT Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients
More informationSummary. Introduction
Osteoarthritis and Cartilage (2002) 10, 290 296 2002 Published by Elsevier Science Ltd on behalf of OsteoArthritis Research Society International 1063 4584/01/040290+07 $22.00/0 doi:10.1053/joca.2001.0510,
More informationT he WOMAC (Western Ontario and McMaster
8 EXTENDED REPORT Validation and patient acceptance of a computer touch screen version of the WOMAC 3.1 osteoarthritis index H A Bischoff-Ferrari, M Vondechend, N Bellamy, R Theiler... See end of article
More informationCharacteristics of selective and non-selective NSAID use in Scotland
Characteristics of selective and non-selective NSAID use in Scotland Alford KMG 1, Simpson C 1, Williams D 2 1 Department of General Practice & Primary Care, The University of Aberdeen. 2 Department of
More informationARD Online First, published on April 13, 2004 as /ard
ARD Online First, published on April 13, 2004 as 10.1136/ard.2003.020313 Patient preference for, or Celecoxib Efficacy Studies (PACES): Two randomized placebo-controlled cross-over clinical trials in patients
More informationReceived: 11 Sep 2006 Revisions requested: 6 Nov 2006 Revisions received: 3 Jan 2007 Accepted: 31 Jan 2007 Published: 31 Jan 2007
Vol 9 No 1 Research article Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib
More informationModelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M
Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M Record Status This is a critical abstract of an economic
More informationREXON-AGE therapy in the treatment of arthrosis
Presidio Ospedaliero di Cittadella Unità Operativa Autonoma ANESTESIA RIANIMAZIONE E TERAPIA DEL DOLORE Direttore: Dott. Giandomenico BABBOLIN Via Riva Ospedale 35013 Cittadella / Padova Tel. 049.942.48.01/3
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationPapers. Abstract. Introduction. Methods. Jonathan J Deeks, Lesley A Smith, Matthew D Bradley
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials Jonathan J Deeks, Lesley
More informationPatient Treatment Preferences for Osteoporosis
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 55, No. 5, October 15, 2006, pp 729 735 DOI 10.1002/art.22229 2006, American College of Rheumatology ORIGINAL ARTICLE Patient Treatment Preferences
More informationSafety and efficacy of flavocoxid compared with naproxen in subjects with osteoarthritis of the knee: a pilot study
Osteoarthritis and Cartilage. 15(suppl B):B91 Safety and efficacy of flavocoxid compared with naproxen in subjects with osteoarthritis of the knee: a pilot study Levy R*, Saikovsky R, Shmidt E, Khokhlov
More informationInternational Cartilage Repair Society
OsteoArthritis and Cartilage (2004) 12, 389 399 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.joca.2004.02.001 International Cartilage
More informationMonth/Year of Review: January 2012 Date of Last Review: February 2007
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January 2012 Date of Last Review:
More informationARD Online First, published on July 1, 2004 as /ard
ARD Online First, published on July 1, 2004 as 10.1136/ard.2003.019307 Validation and Patient Acceptance of a Computer Touch Screen Version of the WOMAC 3.1 Osteoarthritis Index Heike A Bischoff-Ferrari,
More informationCOMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Osteoarthritis Pain
More informationNonsteroidal anti-inflammatory drugs (NSAIDs) are
GASTROENTEROLOGY 2003;125:389 395 Gastrointestinal Health Care Resource Utilization With Chronic Use of COX-2 Specific Inhibitors Versus Traditional NSAIDs LOREN LAINE,* JENIFER WOGEN, and HOLLY YU *University
More informationO steoarthritis is a major source of morbidity, disability,
70 EXTENDED REPORT First line treatment of knee osteoarthritis in outpatients in France: adherence to the EULAR 2000 recommendations and factors influencing adherence L Denoeud, B Mazières, C Payen-Champenois,
More informationDrug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs) Preliminary Scan Report #2 May 2014 Last Report: Update #4 (November 2010) Last Preliminary Scan: July 2013 The purpose of reports is to make
More informationQuality measures in osteoarthritis
Quality measures in osteoarthritis M.C. Hochberg Marc C. Hochberg, MD, MPH, Professor of Medicine and Epidemiology and Preventive Medicine, Head, Division of Rheumatology and Clinical Immunology, University
More informationThis document has not been circulated to either the industry or Consultants within the Suffolk system.
New Medicine Report Document Status COX II Inhibitors In Acute Analgesia For Suffolk Drug & Therapeutics Committee Date of Last Revision 15 th February 2002 Reviewer s Comments There seems to be a growing
More informationPrincipal Investigator. General Information. Conflict of Interest. Certification Published on The YODA Project (
Principal Investigator First Name: Liana Last Name: Fraenkel Degree: MD, MPH Primary Affiliation: Yale University School of Medicine E-mail: christine.ramsey@gmail.com Phone number: 610-613-6745 Address:
More informationPain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain
Pain therapeutics Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain James McCormack, Pharm.D. Professor Faculty of Pharmaceutical Sciences, UBC Common types of pain killers
More informationDatabase of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown
More informationInternational Cartilage Repair Society
OsteoArthritis and Cartilage (2006) 14, 1111e1118 ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.joca.2006.05.004 An analgesic model
More informationT he choice of an outcome measure is a major step in the
29 EXTENDED REPORT Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement F Tubach, P Ravaud, G Baron, B Falissard,
More informationIs Curcumin Effective in Reducing Pain in Arthritis Patients?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is Curcumin Effective in Reducing Pain
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 January 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 January 2013 The opinion adopted by the Transparency Committee on 4 July 2012 was given a hearing on 5 December
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Celebrex) Reference Number: CP.CPA.239 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationA Cohort Study of NSAID Use and the Management of Related Gastrointestinal Symptoms by Primary Care Patients
A Cohort Study of NSAID Use and the Management of Related Gastrointestinal Symptoms by Primary Care Patients Christopher V. Chambers, MD, Walter L. Straus, MD, MPH, James J. Diamond, PhD, Lori A. Trapani,
More informationIroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults
Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed
More informationDrug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report
More informationTRANSPARENCY COMMITTEE OPINION. 26 November 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 26 November 2008 CHONDROSULF 400 mg, capsule Box containing 84 capsules (CIP: 335 917-3) CHONDROSULF 400 mg, granules
More informationPhysiotherapy Services for People with Hip and Knee Arthritis in Ontario
Arthritis Community Research & Evaluation Unit (ACREU) Physiotherapy Services for People with Hip and Knee Arthritis in Ontario March, 2003 Prepared by: *Address for correspondence: Arthritis Community
More informationNSAIDs: Side Effects and Guidelines
NSAIDs: Side Effects and James J Hale FY1 Department of Anaesthetics Introduction The non-steroidal anti-inflammatory drugs (NSAIDs) are a diverse group of drugs that have analgesic, antipyretic and anti-inflammatory
More informationAN NSAID WITH A BALANCED COX-1 & COX-2 INHIBITORY EFFECT
AN NSAID WITH A BALANCED COX-1 & COX-2 INHIBITORY EFFECT A balanced cox-1 and cox-2 inhibitor Metabolisim and Bioavailabillty of Lornoxicam (3) Relative selectivity of agents as inhibitors of cox-1 and
More informationIroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low
More informationPRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation
PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY This audit has been designed to ensure that patients
More informationSpecial article: Response criteria for clinical trials on osteoarthritis of the knee and hip
OsteoArthritis and Cartilage (2000) 8, 395 403 2000 OsteoArthritis Research Society International 1063 4584/00/060395+09 $35.00/0 doi:10.1053/joca.2000.0361, available online at http://www.idealibrary.com
More informationIntraarticular platelet-rich plasma injection in the treatment of knee osteoarthritis: review and recommendations.
Am J Phys Med Rehabil. 2014 Nov;93(11 Suppl 3):S108-21. doi: 10.1097/PHM.0000000000000115. Intraarticular platelet-rich plasma injection in the treatment of knee osteoarthritis: review and recommendations.
More informationMaria Lourdes R. Bernardo and Alfredo C. Azarcon, Jr. Department of Rehabi/itation Medicine, Veterans Memorial Medica! Center
A Randomized Controlled Trial on the Effects of Oral Collagen Treatment on the Media) Knee Joint Space aod Functional Outcome among Veterans Memorial Medical Center Patients Diagnosed with Osteoarthritis
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: ER Injection (Zilretta) Reference Number: CP.PHAR.371 Effective Date: 01.09.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the
More informationSawtooth Software. The Number of Levels Effect in Conjoint: Where Does It Come From and Can It Be Eliminated? RESEARCH PAPER SERIES
Sawtooth Software RESEARCH PAPER SERIES The Number of Levels Effect in Conjoint: Where Does It Come From and Can It Be Eliminated? Dick Wittink, Yale University Joel Huber, Duke University Peter Zandan,
More informationEffectiveness of True Acupuncture as an Adjunct to Standard Care or Electro-Physiotherapy in Osteoarthritis of the Knee
Cronicon OPEN ACCESS ORTHOPAEDICS Research article Effectiveness of True Acupuncture as an Adjunct to Standard Care or Electro-Physiotherapy in Osteoarthritis of Dimitar Tonev 1 *, Stoyka Radeva 2 and
More informationOsteoarthritis Research Society /98/ $12.00/0
Osteoarthritis and Cartilage (1998) 6, (Supplement A), 31 36 9 1998 Osteoarthritis Research Society 1063-4584/98/030031 + 06 $12.00/0 OSTEOARTHRITIS and CARTILAGE Efficacy and tolerability of oral chondroitin
More informationThe Relationship Between Clinical Activity And Function In Ankylosing Spondylitis Patients
Bahrain Medical Bulletin, Vol.27, No. 3, September 2005 The Relationship Between Clinical Activity And Function In Ankylosing Spondylitis Patients Jane Kawar, MD* Hisham Al-Sayegh, MD* Objective: To assess
More informationTECHNOLOGY OVERVIEW. Issue 6 February Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis
TECHNOLOGY OVERVIEW Issue 6 February 2002 Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis Publications can be requested from: CCOHTA 110-955 Green
More informationSafety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis
1. Title: Safety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis 2. Background: The population of older individuals with rheumatoid arthritis
More informationBlood-nourishing and Hard-softening Capsule Costs Less in the Management of Osteoarthritic Knee Pain: A Randomized Controlled Trial
Advance Access Publication 26 July 2005 ecam 2005;2(3)363 368 doi:10.1093/ecam/neh104 Original Article Blood-nourishing and Hard-softening Capsule Costs Less in the Management of Osteoarthritic Knee Pain:
More informationIbuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception
Aliment Pharmacol Ther 2000; 14: 187±191. Ibuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception C. J. HAWKEY 1,D.J.E.CULLEN 1,9,G.PEARSON 1,S.HOLMES
More informationInternational Journal of Orthopaedics Sciences 2017; 3(1): Dr. Sunil Kumar TR and Dr. Harish YS
2017; 3(1): 658-663 ISSN: 2395-1958 IJOS 2017; 3(1): 658-663 2017 IJOS www.orthopaper.com Received: 07-11-2016 Accepted: 08-12-2016 Dr. Sunil Kumar TR Senior Resident, ESIC Medical College and Model Hospital
More informationHome based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial
Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial K S Thomas, K R Muir, M Doherty, A C Jones, S C O Reilly, E J Bassey on behalf of the Community Osteoarthritis
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Celebrex) Reference Number: CP.PMN.122 Effective Date: 01.01.07 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationDecision makers have said that for pharmacoeconomic
Verification of a Decision Analytic Model Assumption Using Real-World Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s) Emily R. Cox, PhD; Brenda Motheral,
More informationIs Phlogenzym Effective in Reducing Moderate to Severe Osteoarthritis Pain in Adults?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2013 Is Phlogenzym Effective in Reducing Moderate
More informationThe Effect of Colchicine in Improving the Symptoms of Patients with Knee Osteoarthritis
Original Article J Babol Univ Med Sci Vol 18, Issu 11; Nov 2016. P:7-13 DOI: The Effect of Colchicine in Improving the Symptoms of Patients with Knee Osteoarthritis A. Amirpour(MD) 1, M.A. Mousavi(MD)
More informationPRIMARY CARE BRIEFING GLUSARTEL (GLUCOSAMINE SULPHATE)
Summary This Primary Care Briefing informs healthcare professionals of a new preparation of glucosamine sulphate, Glusartel, licensed for the relief of symptoms in mild to moderate osteoarthritis of the
More informationBritish Medical Journal. June 3, 2006;332: Patricia M Kearney, Colin Baigent, Jon Godwin, Heather Halls, Jonathan R Emberson, Carlo Patrono
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials 1 British Medical Journal June 3,
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 November 2013 FLEXEA 625 mg, tablet Box of 60 tablets (CIP: 34009 380 534 2 5) Box of 180 tablets (CIP: 34009 380
More informationWAIT TIMES TO RHEUMATOLOGY AND REHABILITATION SERVICES: IS RHEUMATOID ARTHRITIS PRIORITIZED?
WAIT TIMES TO RHEUMATOLOGY AND REHABILITATION SERVICES: IS RHEUMATOID ARTHRITIS PRIORITIZED? Ashley Delaurier PT M.Sc. Candidate Biomedical Sciences University of Montreal ashley.delaurier@umontreal.ca
More informationDyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac
Aliment Pharmacol Ther 2002; 16: 819 827. Dyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac J. L. GOLDSTEIN*, G. M. EISEN, T. A. BURKEà, B. M. PEÑA, J. LEFKOWITH
More informationUPDATES ON MANAGEMENT OF OSTEOARTHRITIS
UPDATES ON MANAGEMENT OF OSTEOARTHRITIS August 10, 2014 Dr. Suneil Kapur Assistant Professor of Medicine, University of Ottawa Associate Staff Rheumatologist, The Ottawa Hospital Learning Objectives Upon
More informationDisclosure. Learning Objectives 1/17/2018. Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with NSAID Use
Disclosure Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with Liz Van Dril, PharmD, BCPS PGY2 Ambulatory Care Resident January 17 th, 2018 Dr. Liz Van Dril has no actual or potential
More informationNSAIDs. NSAIDs are important but they can have side effects.
NSAIDs Pain Treatment Nonsteroidal anti-inflammatory drugs (NSAIDs) are often recommended for initial treatment of pain and can be added to more powerful drugs to treat worse pain. Acetaminophen, such
More information4 2 Osteoarthritis 1
Osteoarthritis 1 Osteoarthritis ( OA) Osteoarthritis is a chronic disease and the most common of all rheumatological disorders. It particularly affects individuals over the age of 65 years. The prevalence
More informationEffective management of gastrointestinal PROCEEDINGS EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS *
EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS * David A. Peura, MD, FACP, FACG ABSTRACT *This article is based on a presentation given by Dr Peura at the PRI-MED
More informationNON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK. Advances in Cardiac Arrhythmias and Great Innovations in Cardiology
NON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK Advances in Cardiac Arrhythmias and Great Innovations in Cardiology Torino, October 15, 2016 Giuseppe Di Pasquale Direttore Dipartimento Medico
More informationDrug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs () UPDATED FINAL REPORT #1 September 2003 Mark Helfand, MD, MPH Oregon Evidence-based Practice Center Oregon
More informationIs Ginger Effective in Reducing Knee Pain in Adults With Osteoarthritis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Ginger Effective in Reducing Knee
More informationNew Medicine Report (Adopted by the CCG until review and further
New Medicine Report (Adopted by the CCG until review and further DEXIBUPROFEN notice) Document Status Decision made at Suffolk D&TC 7 th September 2006 Traffic Light Decision Double Green Prescriber s
More information(minutes for web publishing)
Rheumatology Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 17 October 2017 (minutes for web publishing) Rheumatology Subcommittee minutes are published in
More informationCardiovascular Risk of Celecoxib in 6 Randomized Placebo-controlled Trials: The Cross Trial Safety Analysis
Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-controlled Trials: The Cross Trial Safety Analysis Scott D. Solomon, MD, Janet Wittes, PhD, Ernest Hawk, MD, MPH for the Celecoxib Cross Trials
More informationIMMEDIATE DICLOFENAC NEW CONTRAINDICATIONS AND WARNINGS AFTER A EUROPE-WIDE REVIEW OF CARDIOVASCULAR SAFETY
Finance, EHealth and Pharmaceuticals Directorate Pharmacy and Medicines Division T: 0131-244 2528 E: irene.fazakerley@scotland.gsi.gov.uk 1. Medical Directors 2. Directors of Public Health 3. Directors
More informationharmacologyonline Key-words: Osteoarthritis therapy, nonsteroidal anti-inflammatory drug, dexketoprofen trometamol, diclofenac sodium
harmacologyonline Archives 2012 vol.3 50-57 December 30, 2012 A COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF DEXKETOPROFEN TROMETAMOL VERSUS DICLOFENAC SODIUM IN THE SYMPTOMATIC TREATMENT OF KNEE
More informationDrug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report May 2004 The purpose of this report is to make available information regarding the
More informationAnalgesic Subcommittee of PTAC Meeting held 1 March 2016
Analgesic Subcommittee of PTAC Meeting held 1 March 2016 (minutes for web publishing) The Analgesic Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and
More informationHelpline No:
ARTHRITIS FOUNDATION Registered Nonprofit Organisation - No. 002-847 NPO Helpline No: 0861 30 30 30 DRUGS AND ARTHRITIS This information leaflet is published by the Arthritis Foundation as part of our
More informationRisk of myocardial infarction with use of selected nonsteroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis
1/5 We use cookies to improve our service and to tailor our content and advertising to you. More info Home / Archive / Volume 77, Issue 8 Article Text Article menu Clinical and epidemiological research
More informationOsteoarthritis (OA), Safety & Efficacy of Glucosamine & Chondroitin in Osteoarthritis. Clinical studies. show these. agents are very.
FEATURE Safety & Efficacy of Glucosamine & Chondroitin in Osteoarthritis by DARRELL T. HULISZ, Pharm.D., R.Ph. Assistant Professor of Family Medicine Case Western Reserve University School of Medicine;
More information... REPORTS... The Use and Effect of Analgesics in Patients Who Regularly Drink Alcohol. Richard C. Dart, MD, PhD
... REPORTS... The Use and Effect of Analgesics in Patients Who Regularly Drink Alcohol Richard C. Dart, MD, PhD Abstract Analgesic consumption poses special risks for regular users of alcohol. Among the
More informationChristopher J. Swearingen, Sarah Kennedy, Jeyanesh R.S. Tambiah. Samumed LLC, San Diego, CA, USA
Radiographic Outcomes Were Concordant with Pain and Function Response: Post-Hoc Analysis from a Phase 2 Study of SM04690, a Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment Christopher J. Swearingen,
More informationThe Efficacy of Continuous Versus Intermittent Celecoxib Treatment in Osteoarthritis Patients with Body Mass Index 30 and <30 kg/m 2
Send Orders of Reprints at reprints@benthamscience.net 32 The Open Rheumatology Journal, 2013, 7, 32-37 Open Access The Efficacy of Continuous Versus Intermittent Treatment in Osteoarthritis Patients with
More informationEffective Health Care Program
Comparative Effectiveness Review Number 38 Effective Health Care Program Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review Executive Summary Background Osteoarthritis
More informationRisk Management Plan Etoricoxib film-coated tablets
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Osteoarthritis (OA): OA is a condition in which the cartilage of the joints is broken down. This causes stiffness, pain and leads
More informationPDP 406 CLINICAL TOXICOLOGY
PDP 406 CLINICAL TOXICOLOGY Pharm.D Fourth Year NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) Mr.D.Raju.M.Pharm., Lecturer OPTIONS FOR LOCAL IMPLEMENTATION (1) NPC. KEY THERAPEUTIC TOPICS MEDICINES MANAGEMENT
More informationGlucosamine May Reduce Pain in Individuals with Knee Osteoarthritis
1 Glucosamine May Reduce Pain in Individuals with Knee Osteoarthritis Prepared by: Jacqueline Pierce, MSc (PT) candidate, Queen's University Date: April 2005 (planned review date April 2007) Clinical Scenario:
More informationThe medical treatment of rheumatoid arthritis has been dramatically improved with the
DOI: 10.5124/jkma.2010.53.10.871 pissn: 1975-8456 eissn: 2093-5951 http://jkma.org Focused Issue of This Month Medical treatment of rheumatoid arthritis (I): Nonsteroidal anti-inflammatory drugs, disease
More informationPain in Osteoarthritis
Pain in Osteoarthritis By Edward L. Treadwell, MD Professor of Medicine- Rheumatology/Immunology Brody School of Medicine at East Carolina University School of Medicine Greenville, NC 27834 E-mail: treadwelle@ecu.edu
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationEfficacy and Tolerability of Celecoxib versus Naproxen in Patients with Osteoarthritis of the Knee: a Randomized, Double-blind, Double-dummy Trial
The Journal of International Medical Research 2012; 40: 1357 1370 Efficacy and Tolerability of Celecoxib versus Naproxen in Patients with Osteoarthritis of the Knee: a Randomized, Double-blind, Double-dummy
More informationImplementing AHRQ Effective Health Care Reviews Helping Clinicians Make Better Treatment Choices
Implementing AHRQ Effective Health Care Reviews Helping Clinicians Make Better Treatment Choices Gout: Diagnosis and Management Practice Pointers by MATTHEW R. NOSS, DO, MSEd, U.S. Army Health Clinic,
More informationReview Article. Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) Safety Profile of NSAID
Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) R. Stoilov: University Hospital St Ivan Rilski, Clinic of Rheumatology Contact: Rumen Stoilov, Clinic of Rheumatology, University Hospital St
More informationHealth Plan Member Experience With Point-of-Service Prescription Step Therapy
ORIGINAL RESEARCH Health Plan Member Experience With Point-of-Service Prescription Step Therapy EMILY R. COX, RPh, PhD; ROCHELLE HENDERSON, MPA; and BRENDA R. MOTHERAL, RPh, MBA, PhD ABSTRACT OBJECTIVE:
More informationOSTEOARTHRITIS An introduction to aging science brought to you by the American Federation for Aging Research
infoaging guides DISEASES OF AGING OSTEOARTHRITIS An introduction to aging science brought to you by the American Federation for Aging Research WHAT IS OSTEOARTHRITIS? Osteoarthritis (OA) is the most common
More informationNew Medicines Profile
New Medicines Profile May 2008 Issue No. 08/05 (Alateris ) Concise evaluated information to support the managed entry of new medicines in the NHS Brand Name, (Manufacturer): Alateris (William Ransom &
More information